CLINICAL RESEARCH
Our Clinical Trials Shape the Future of Cancer Care
Our technologies and services are designed to support patients by making cancer care more accessible, affordable, and liveable. Our clinical research program is designed to build the evidence for a new future for cancer care.
Information on this web page pertains to pre-clinical or clinical-stage medical devices in development that have not been approved by the Food and Drug Administration. The safety and effectiveness of these technologies have not yet been established.
Be part of building a better future for cancer care.
We're building technologies and services to re-imagine cancer care - from where we treat cancer to how we support people with cancer.
Our clinical research program aims to produce high quality data in support of quality-of-life and cost of care management in cancer care. If you're a patient, provider, or researcher, and you want to participate in the future of cancer care - let us know.
Active Clinical Research Opportunities
We are actively enrolling clinical sites for participation in our clinical research program across the United States.
LOTUS-ONE: Financial Toxicity Research
LOTUS-ONE is a series of single-center feasibility studies aiming to establish the financial benefit of home infusion services.
IMPACT: Reducing Peripheral Neuropathy
IMPACT is a multinational randomized study aiming to demonstrate the efficacy of a new therapy to reduce CIPN occurence.
HORIZON: Device-Led Home Infusion
HORIZON is a feasibility study of patient-led home infusion of select immunotherapy agents using novel medical device(s).
Our clinical research focus areas
Luminate's mission is to make cancer care more human - because the system isn't working for the people in it. Our clinical research division focuses on building the evidence for new technologies and services that can make cancer care better.
We develop and pilot new technologies alongside partnering with industry, academia, physicians and patient advocates to identify and answer important research questions for the future of cancer care.
Interested in a research collaboration? Let us know! We want to hear about new ideas for how we can make cancer care easier, more affordable, or less burdensome for patients.
Lilac is an investigational medical device and has not been approved by the U.S. Food and Drug Administration. The safety and effectiveness of this technology has not yet been established.
The Lotus Infusion Set and Lotus SC devices are in development and have not been approved by the U.S. Food and Drug Administration. The safety and effectiveness of these technologies have not yet been established.
Lily is an investigational medical device and has not been approved by the U.S. Food and Drug Administration. The safety and effectiveness of this technology has not yet been established.
We’re partnering with organizations to bring more efficient, outcome-focused cancer care into the real world.
If you’re interested in piloting, modelling cost impact, or discussing integration then we’d love to hear from you.
